ArticleLymphatic research and biology2014
Cytokine candidate genes predict the development of secondary lymphedema following breast cancer surgery.
Article in Lymphatic research and biology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 68 citations in OpenAlex.
- Therapeutic Potential of Lymphatic Endothelial Progenitor Cells in Secondary Lymphedema: A Preclinical Murine Study.Biomedicines · 2026Article
- Identification of a Cytokine Biomarker for Prognostic Modeling of Breast Cancer-Related Lymphedema.Cancer research communications · 2026Article
- From stasis to systematics: deciphering the pathophysiology of secondary lymphedema through omics.Frontiers in immunology · 2026Review
- Uncovering potential molecular biomarkers for cancer-associated secondary lymphedema through integrated analyses of RNA-sequencing, machine learning, and clinical data.Frontiers in oncology · 2026Article
- Breast Cancer-Related Lymphedema: Nursing-Led Strategies - A Narrative Review.Journal of multidisciplinary healthcare · 2026Review
- Etiology and treatment of cancer-related secondary lymphedema.Clinical & experimental metastasis · 2024Review
- The Role of Inflammation in Lymphedema: A Narrative Review of Pathogenesis and Opportunities for Therapeutic Intervention.International journal of molecular sciences · 2024Review
- Review
- Recent Advances in Therapeutic Modalities Against Breast Cancer-Related Lymphedema: Future Epigenetic Landscape.Lymphatic research and biology · 2023Review
- Current Mechanistic Understandings of Lymphedema and Lipedema: Tales of Fluid, Fat, and Fibrosis.International journal of molecular sciences · 2022Review
- Secondary lymphedema from cancer therapy.Clinical & experimental metastasis · 2022Review
- Hypoxia and Hypoxia-Inducible Factors in Lymphedema.Frontiers in pharmacology · 2022Review
- NR4A2 may be a potential diagnostic biomarker for myocardial infarction: A comprehensive bioinformatics analysis and experimental validation.Frontiers in immunology · 2022Article
- Genetic Predictors of Response to Acupuncture or Cognitive Behavioral Therapy for Insomnia in Cancer Survivors: An Exploratory Analysis.Journal of pain and symptom management · 2021Article
- Massive limb lymphedema as the initial presentation of multiple myeloma: a case report.Translational cancer research · 2021Article
- Model-Based Patterns of Lymphedema Symptomatology: Phenotypic and Biomarker Characterization.Current breast cancer reports · 2021Article
- Crosstalk Between microRNAs and the Pathological Features of Secondary Lymphedema.Frontiers in cell and developmental biology · 2021Review
- Study of a supplement and a genetic test for lymphedema management.Acta bio-medica : Atenei Parmensis · 2020Article
- The effect of interleukin 10 polymorphisms on breast cancer susceptibility in Han women in Shaanxi Province.PloS one · 2020Article
- Integrating Biological Advances Into the Clinical Management of Breast Cancer Related Lymphedema.Frontiers in oncology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundLymphedema (LE) is a frequent complication following breast cancer treatment. While progress is being made in the identification of phenotypic risk factors for the development of LE, little information is available on the molecular characterization of LE. The purpose of this study was to determine if variations in pro- and anti-inflammatory cytokine genes were associated with LE following breast cancer treatment. METHODS AND
resultsBreast cancer patients completed a number of self-report questionnaires. LE was evaluated using bioimpedance spectroscopy. Genotyping was done using a custom genotyping array. No differences were found between patients with (n=155) and without LE (n=387) for the majority of the demographic and clinical characteristics. Patients with LE had a significantly higher body mass index, more advanced disease, and a higher number of lymph nodes removed. Genetic associations were identified for three genes (i.e., interleukin (IL4) 4 (rs2227284), IL 10 (rs1518111), and nuclear kappa factor beta 2 (NFKB2 (rs1056890)) associated with inflammatory responses.
conclusionsThese genetic associations suggest a role for a number of pro- and anti-inflammatory genes in the development of LE following breast cancer treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.